# Drug Pricing: Resources

This section provides a curated list of key research, reports, data sources, and organizations focused on pharmaceutical drug pricing policy in the United States.

---

## Academic Research

### Peer-Reviewed Studies

- Kesselheim, A.S., Avorn, J., & Sarpatwari, A. "The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform." *JAMA* 316, no. 8 (2016): 858-871. <https://doi.org/10.1001/jama.2016.11237>
- Dafny, L., Ody, C., & Schmitt, M. "When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization." *American Economic Journal: Economic Policy* 9, no. 2 (2017): 91-123. <https://doi.org/10.1257/pol.20150588>
- Sarpatwari, A., DiBello, J., Engel, M., & Kesselheim, A.S. "Are Patent Settlements in the Pharmaceutical Industry Anticompetitive?" *Journal of Law and the Biosciences* 6, no. 1 (2019): 1-28. <https://doi.org/10.1093/jlb/lsz006>
- Wouters, O.J., McKee, M., & Luyten, J. "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018." *JAMA* 323, no. 9 (2020): 844-853. <https://doi.org/10.1001/jama.2020.1166>
- Sachs, R.E. "The Inflation Reduction Act -- Drug Pricing Provisions and Implications." *New England Journal of Medicine* 387, no. 14 (2022): 1257-1259. <https://doi.org/10.1056/NEJMp2209621>
- Hernandez, I., Guo, J., & Dickson, S. "Trajectories of Drug Pricing in the United States, 2007-2022." *JAMA Network Open* 7, no. 3 (2024): e243102. <https://doi.org/10.1001/jamanetworkopen.2024.3102>
- Lexchin, J. "Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications." *Science and Engineering Ethics* 18, no. 2 (2012): 247-261. <https://doi.org/10.1007/s11948-011-9265-3>

### Working Papers and White Papers

- Lakdawalla, D., & Sood, N. "Innovation and the Welfare Effects of Public Drug Insurance." *NBER Working Paper No. 16734*. 2022. <https://www.nber.org/papers/w16734>
- Frank, R.G., & Nichols, L.M. "Medicare Drug-Price Negotiation -- Why Now ... and How." *Brookings Institution*. 2023. <https://www.brookings.edu/articles/medicare-drug-price-negotiation/>
- Blumenthal, D., & Seervai, S. "Drug Pricing Reform: Lessons from the Inflation Reduction Act." *Commonwealth Fund Issue Brief*. 2023. <https://www.commonwealthfund.org/>

---

## Government Reports and Data

### Federal Agencies

- Centers for Medicare & Medicaid Services. "Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026." August 2024. <https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation>
- Centers for Medicare & Medicaid Services. "National Health Expenditure Data." Updated annually. <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData>
- Office of the Assistant Secretary for Planning and Evaluation (ASPE). "Comparison of Drug Prices Between the United States and Other Nations." 2024. <https://aspe.hhs.gov/reports/drug-pricing>
- Federal Trade Commission. "Interim Staff Report on Pharmacy Benefit Managers." July 2024. <https://www.ftc.gov/reports/pharmacy-benefit-managers-report>
- Food and Drug Administration. "Generic Drug Access and Savings Reports." Updated annually. <https://www.fda.gov/drugs/generic-drugs/generic-drug-access-savings-us>
- FDA Office of Generic Drugs. "ANDA Approval Reports." Updated monthly. <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-statistics>

### Congressional Reports

- Congressional Budget Office. "Prescription Drugs: Spending, Use, and Prices." January 2022. <https://www.cbo.gov/publication/57772>
- Congressional Budget Office. "Estimated Budgetary Effects of H.R. 5376, the Inflation Reduction Act of 2022." August 2022. <https://www.cbo.gov/publication/58455>
- Congressional Research Service. "Medicare Part D Prescription Drug Benefit." Report R40611. Updated 2024. <https://crsreports.congress.gov/product/pdf/R/R40611>
- Congressional Research Service. "The 340B Drug Pricing Program." Report R44235. Updated 2024. <https://crsreports.congress.gov/product/pdf/R/R44235>
- Government Accountability Office. "Drug Industry: Profits, Research and Development Spending, and Merger and Acquisition Deals." GAO-18-40 (2017). <https://www.gao.gov/products/gao-18-40>
- Government Accountability Office. "Medicare Part D: CMS Should Monitor Effects of the Inflation Reduction Act's Drug Pricing Provisions." GAO-24-106285 (2024). <https://www.gao.gov/products/gao-24-106285>

### Agency Data Portals

- CMS. Medicare Drug Spending Dashboard. <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs> - Drug-level spending data for Part B and Part D
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. <https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book> - Patent and exclusivity listings for approved drugs
- HRSA. 340B Drug Pricing Program. <https://www.hrsa.gov/opa> - Program data, covered entity listings, and pricing information
- Office of National Drug Control Policy (ONDCP). Drug Control Budget. <https://www.whitehouse.gov/ondcp/> - Federal drug control spending data

---

## Books

- Mazzucato, M. *The Entrepreneurial State: Debunking Public vs. Private Sector Myths*. Anthem Press, 2013. - Argues that public investment drives innovation, including in pharmaceuticals
- Angell, M. *The Truth About the Drug Companies: How They Deceive Us and What to Do About It*. Random House, 2004. - Former NEJM editor's critique of pharmaceutical industry pricing and marketing
- Posner, E. & Weyl, E.G. *Radical Markets: Uprooting Capitalism and Democracy for a Just Society*. Princeton University Press, 2018. - Includes analysis of patent reform and pharmaceutical pricing
- Emanuel, E.J. *The Trillion Dollar Revolution: How the Affordable Care Act Transformed Politics, Law, and Health Care in America*. PublicAffairs, 2020. - Includes chapters on drug pricing provisions in the ACA
- Sood, N., & Shih, T. *The Future of Drug Pricing*. Cambridge University Press, 2024. - Comprehensive academic analysis of drug pricing mechanisms and reform options

---

## Think Tank Analysis

### Research Organizations

- RAND Corporation. "International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies." 2024. <https://www.rand.org/pubs/research_reports/RRA788-1.html> - Definitive comparison of U.S. and international drug prices
- Kaiser Family Foundation (KFF). "Key Facts About the Prescription Drug Market." Updated 2024. <https://www.kff.org/health-costs/issue-brief/key-facts-about-the-prescription-drug-market/> - Regularly updated overview of drug spending, pricing, and patient burden
- Commonwealth Fund. "U.S. Health Care from a Global Perspective." 2024. <https://www.commonwealthfund.org/publications/issue-briefs/2024/jan/us-health-care-global-perspective-2023> - International comparisons including pharmaceutical spending
- Brookings Institution. "Reforming Drug Pricing." Multiple publications. <https://www.brookings.edu/topic/health-care-costs/> - Policy analysis of negotiation, reference pricing, and competition
- Initiative for Medicines, Access and Knowledge (I-MAK). "Overpatented, Overpriced." Multiple reports. <https://www.i-mak.org/overpatented-overpriced/> - Patent analysis for high-revenue drugs

### Policy Briefs

- Urban Institute. "The Effects of Drug Price Negotiation on Prescription Drug Spending." 2023. <https://www.urban.org/research>
- American Enterprise Institute. "Drug Pricing and Innovation: A Guide to the Debate." 2023. <https://www.aei.org/health-policy/>
- Center for American Progress. "Comprehensive Drug Pricing Reform." 2024. <https://www.americanprogress.org/topics/health-care/>

---

## Organizations and Advocacy Groups

| Organization | Focus | Type | Website |
|--------------|-------|------|---------|
| AARP | Medicare drug pricing; patient affordability; IRA implementation | Advocacy (38M+ members) | <https://www.aarp.org/health/drugs-supplements/> |
| Patients for Affordable Drugs | Drug pricing reform advocacy; patient stories; legislative campaigns | Non-profit advocacy (no pharma funding) | <https://www.patientsforaffordabledrugs.org/> |
| Families USA | Healthcare affordability including drug pricing | Non-profit advocacy | <https://familiesusa.org/> |
| PhRMA | Pharmaceutical industry trade association; opposes government price controls | Industry trade association | <https://www.phrma.org/> |
| Association for Accessible Medicines (AAM) | Generic and biosimilar manufacturer trade association | Industry trade association | <https://accessiblemeds.org/> |
| National Community Pharmacists Association (NCPA) | Independent pharmacy interests; PBM reform | Professional association | <https://www.ncpa.org/> |
| West Health | Drug pricing research and policy; senior healthcare affordability | Non-profit research | <https://www.westhealth.org/> |
| Arnold Ventures | Drug pricing research funding; evidence-based policy | Philanthropy | <https://www.arnoldventures.org/areas-of-focus/health-care/> |
| I-MAK | Pharmaceutical patent analysis; access to medicines | Non-profit research/advocacy | <https://www.i-mak.org/> |

---

## Data Sources

| Dataset | Provider | Update Frequency | URL | Description |
|---------|----------|------------------|-----|-------------|
| National Health Expenditure Data | CMS | Annual | <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData> | Total drug spending by payer category |
| Medicare Part D Drug Spending Dashboard | CMS | Annual | <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs> | Drug-level Medicare spending |
| OECD Health Statistics | OECD | Annual | <https://www.oecd.org/health/health-data.htm> | International drug spending and pricing comparisons |
| IQVIA Institute Reports | IQVIA | Annual/Quarterly | <https://www.iqvia.com/insights/the-iqvia-institute> | U.S. prescription drug market data |
| Drug Channels Industry Data | Drug Channels Institute | Annual | <https://www.drugchannelsinstitute.com/> | PBM market share, 340B data, gross-to-net analysis |
| KFF Health Tracking Poll | Kaiser Family Foundation | Monthly | <https://www.kff.org/health-costs/poll-finding/> | Public attitudes on drug pricing; cost burden data |
| Orange Book | FDA | Updated continuously | <https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book> | Patent and exclusivity data for approved drugs |
| 340B OPAIS | HRSA | Updated daily | <https://340bopais.hrsa.gov/> | 340B ceiling prices and program data |

---

## News and Journalism

### Investigative Reports

- STAT News. "Pharmalittle" daily newsletter and drug pricing coverage. <https://www.statnews.com/topic/drug-pricing/> - Leading source for pharmaceutical policy journalism
- Kaiser Health News / KFF Health News. Drug pricing investigations. <https://kffhealthnews.org/topics/pharmaceuticals/> - In-depth reporting on patient costs and industry practices
- ProPublica. "Dollars for Docs" and pharmaceutical industry investigations. <https://www.propublica.org/series/dollars-for-docs> - Pharmaceutical industry payment data and accountability
- Reuters Health. "Insulin's Steep Price" series. 2019. <https://www.reuters.com/investigates/> - Investigation of insulin pricing chain

### Ongoing Coverage

- *STAT News*. Pharmaceutical industry and drug pricing. <https://www.statnews.com/> - Daily coverage of pharmaceutical policy, pricing, and industry
- *Drug Channels* (Adam Fein). PBM and drug pricing analysis. <https://www.drugchannels.net/> - Expert analysis of pharmaceutical distribution and PBM economics
- *KFF Health News*. Patient drug costs and affordability. <https://kffhealthnews.org/> - Patient-focused health policy journalism
- *Endpoints News*. Pharmaceutical R&D and business. <https://endpts.com/> - Biotech and pharmaceutical industry reporting

---

## International Sources

- OECD. "Pharmaceutical Spending and Policies." *Health at a Glance* (Annual). <https://www.oecd.org/health/health-systems/pharmaceutical-spending.htm>
- World Health Organization. "WHO Guideline on Country Pharmaceutical Pricing Policies." 2020. <https://www.who.int/publications/i/item/9789240011878>
- Patented Medicine Prices Review Board (Canada). "Annual Report." <https://www.canada.ca/en/patented-medicine-prices-review.html> - Canadian drug price regulation data
- National Institute for Health and Care Excellence (UK). Methodology and technology appraisals. <https://www.nice.org.uk/> - UK cost-effectiveness assessment methodology
- GKV-Spitzenverband (Germany). AMNOG implementation reports. <https://www.gkv-spitzenverband.de/> - German drug pricing regulation data

---

## Legal Resources

### Case Law

- *FTC v. Actavis, Inc.*, 570 U.S. 136 (2013) - Supreme Court ruled that pay-for-delay settlements can violate antitrust law under rule of reason analysis
- *Daraprim Antitrust Litigation*, No. 20-cv-0706 (S.D.N.Y.) - FTC case against Vyera Pharmaceuticals for maintaining monopoly through anticompetitive distribution restrictions
- *Bristol-Myers Squibb Co. v. Becerra*, No. 23-cv-3335 (D.D.C. 2024) - Constitutional challenge to IRA drug price negotiation (rejected by district court)
- *Merck & Co. v. Becerra*, No. 23-cv-1615 (D.D.C. 2024) - IRA constitutional challenge on Fifth Amendment grounds (rejected by district court)
- *Novo Nordisk v. Becerra*, No. 23-cv-20814 (D.N.J. 2024) - IRA constitutional challenge (rejected by district court)

### Statutory References

- 42 U.S.C. Section 1395w-111 (Medicare Part D non-interference clause, partially repealed by IRA)
- 42 U.S.C. Section 1395w-114c (IRA Medicare Drug Price Negotiation Program)
- 42 U.S.C. Section 256b (340B Drug Pricing Program)
- 21 U.S.C. Section 355 (Hatch-Waxman Act ANDA provisions)
- 42 U.S.C. Section 262(k) (Biologics Price Competition and Innovation Act)
- P.L. 117-169, Sections 11001-11003 (Inflation Reduction Act drug pricing provisions)
- 26 U.S.C. Section 280E (Tax deduction prohibition for cannabis businesses -- referenced in context of federal drug scheduling reform)

---

## Document Navigation

- Up: [Drug Policy](../01-overview.md)
- Previous: [Roadmap](08-roadmap.md)
- Next: [Actions](10-actions.md)
